ArticleJournal of immunology (Baltimore, Md. : 1950)2014
A novel mechanism of B cell-mediated immune suppression through CD73 expression and adenosine production.
Article in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 132 citations in OpenAlex.
- B1 Cells for Life.Immunological reviews · 2026Review
- B Cell Subsets and Atherosclerosis: Updates and Emerging Concepts.Immunological reviews · 2026Review
- Regulatory B Cells at the Crossroads of Epigenetic Control and Immune Homeostasis.Clinical reviews in allergy & immunology · 2026Review
- Disrupting CD22-cis-ligand interactions ameliorates type 1 diabetes and graft rejection by expanding regulatory B cells.PLoS biology · 2026Article
- IL-35 enhances IL-10⁺ breg-mediated immunoregulation and attenuates inflammation and fibrosis in systemic sclerosis.Arthritis research & therapy · 2026Article
- Regulatory B cells: heterogeneity, immunosuppressive networks, and contributions to autoimmune pathogenesis.Frontiers in immunology · 2026Review
- Revisiting B-cell targeted therapies in rheumatoid arthritis: from paradoxical biology to deep immune reset.Frontiers in immunology · 2026Review
- Guardians of immunity: the role of tumour-draining lymph node in cancer immunity.Frontiers in cell and developmental biology · 2026Review
- CyTOF analysis of immune characteristics in cSLE: belimumab treatment and refractory cases.Frontiers in immunology · 2026Article
- Dynamic regulation of hypoxia-associated regulatory CD39Frontiers in immunology · 2026Article
- CD39 and CD73: biological functions, diseases and therapy.Molecular biomedicine · 2025Review
- Direct-in-NOD genetic ablation of Bcl3 leads to complete type 1 diabetes protection.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Distinct B Cell Subsets Changes as Potential Biomarkers of Response to Biologic Therapy in Crohn's Disease.International journal of molecular sciences · 2025Article
- Adenosine-generating CD39Life science alliance · 2025Article
- Revealing the role of regulatory b cells in cancer: development, function and treatment significance.Cancer immunology, immunotherapy : CII · 2025Review
- CD73: a new immune checkpoint for leukemia treatment.Frontiers in immunology · 2025Review
- CD39 is an antibody-secreting B-cell marker that modulates germinal center and antibody responses during infection.Frontiers in immunology · 2025Article
- B-1 cells contribute to increased total IgM and shape IgG autoreactivity profiles in Lyn-/- mice but are not a major source of lupus-associated pathogenic autoantibodies.Frontiers in immunology · 2025Article
- The half-century odyssey of regulatory B cells: from Breg discovery to emerging frontiers.Frontiers in immunology · 2025Review
- The Role of Regulatory B Lymphocytes in Allergic Diseases.Biomedicines · 2024Review
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Immune suppression by regulatory T cells and regulatory B cells is a critical mechanism to limit excess inflammation and autoimmunity. IL-10 is considered the major mediator of B cell-induced immune suppression. We report a novel mechanism for immune suppression through adenosine generation by B cells. We identified a novel population of B cells that expresses CD73 as well as CD39, two ectoenzymes that together catalyze the extracellular dephosphorylation of adenine nucleotides to adenosine. Whereas CD39 expression is common among B cells, CD73 expression is not. Approximately 30-50% of B-1 cells (B220(+)CD23(-)) and IL-10-producing B (B10) cells (B220(+)CD5(+)CD1d(hi)) are CD73(hi), depending on mouse strain, whereas few conventional B-2 cells (B220(+)CD23(+)AA4.1(-)) express CD73. In keeping with expression of both CD73 and CD39, we found that CD73(+) B cells produce adenosine in the presence of substrate, whereas B-2 cells do not. CD73(-/-) mice were more susceptible to dextran sulfate sodium salt (DSS)-induced colitis than wild type (WT) mice were, and transfer of CD73(+) B cells ameliorated the severity of colitis, suggesting that B cell CD73/CD39/adenosine can modulate DSS-induced colitis. IL-10 production by B cells is not affected by CD73 deficiency. Interestingly, adenosine generation by IL-10(-/-) B cells is impaired because of reduced expression of CD73, indicating an unexpected connection between IL-10 and adenosine and suggesting caution in interpreting the results of studies with IL-10(-/-) cells. Our findings demonstrate a novel regulatory role of B cells on colitis through adenosine generation in an IL-10-independent manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.